Ionis Pharmaceuticals(IONS) - 2024 Q1 - Earnings Call Transcript

Company Participants Conference Call Participants These data provided clinical evidence demonstrating for the first time that targeting DGAT2 to reduce hepatic fat production can improve NASH histological endpoints, including improving fibrosis. Study met its primary and key secondary endpoints while also demonstrating that ION224 was safe and well tolerated. These results support advancing this program to the next stage of development. Additionally, we aim to build meaningful relationships with patients an ...